Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax™ Treatment
Disease free survival at 3 years
Key Eligibility Criteria
- Node Positive (NP)
- HER2 1+ or 2+
- HLA A2 or HLA A3 Positive
- No evidence of disease (NED) following Standard of Care
Intradermal injection once per month for 6 months (6 total), followed by boosters shots once every 6 months (5 total) for a total of 11 shots over 3 years.